Abstract
Since the discovery of the endocannabinoid system, a growing body of psychiatric research has emerged focusing on the potential role of this system in schizophrenia. On the basis of earlier epidemiological studies and results from animal models, endocannabinoids and their relation to symptoms are considered in clinical studies as well as in post-mortem analyses of cannabinoid CB1 receptor densities. A possible neurobiological mechanism for the deleterious influence of cannabis use in schizophrenia is discussed, involving the disruption of endogenous cannabinoid signalling and function.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ACC:
-
Anterior cingulate cortex
- CSF:
-
Cerebrospinal fluid
- PCC:
-
Posterior cingulate cortex
References
Andreasson S, Allebeck P, Engstrom A et al. (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483–1486
Andreasson S, Allebeck P, Rydberg U (1989) Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiat Scand 79:505–510
Arseneault L, Cannon M, Poulton R et al. (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br Med J 325:1212–1213
Arseneault L, Cannon M, Witton J et al. (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117
Dean B, Sundram S, Bradbury R et al. (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15
D'Souza CD, Perry E, MacDougall L et al. (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29:1558–1572
D'Souza DC, Abi-Saab WM, Madonick S et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594–608
Eggan SM, Hashimoto T, Lewis DA (2008) Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 65:772–784
Emrich HM, Leweke FM, Schneider U (1997) Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to a dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 56:803–807
Giuffrida A, Parsons LH, Kerr TM et al. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358–363
Giuffrida A, Leweke FM, Gerth CW et al. (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108–2114
Gregg L, Barrowclough C, Haddock G (2007) Reasons for increased substance use in psychosis. Clin Psychol Rev 27:494–510
Henquet C, Krabbendam L, Spauwen J et al. (2005) Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Br Med J 330:11–16
Koethe D, Gerth CW, Neatby MA et al. (2006) Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr Res 88:142–150
Koethe D, Llenos IC, Dulay JR et al. (2007) Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 114:1055–1063
Kovasznay B, Fleischer J, Tanenberg Karant M et al. (1997) Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 23:195–201
Leweke FM, Kampmann C, Radwan M et al. (1998) The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials. Neuropsychobiology 37:104–111
Leweke FM, Giuffrida A, Wurster U et al. (1999a) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665–1669
Leweke FM, Schneider U, Thies M et al. (1999b) Effects of synthetic Δ9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology 142:230–235
Leweke FM, Schneider U, Radwan M et al. (2000) Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 66:175–181
Leweke FM, Koethe D, Gerth CW et al. (2005) The endocannabinoid modulator cannabidiol as an antipsychotic. Results from the first controlled clinical trial in acute schizophrenia. Biol Psychiat 57:S135
Leweke FM, Giuffrida A, Koethe D et al. (2007a) Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 94(1–3):29–36
Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51:273–279
Meltzer HY, Arvanitis L, Bauer D et al. (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161:975–984
Moreau de Tours J-J (1845) Du hachisch et de l'aliénation mentale, Études psychologiques. Paris, Fortin et Masson
Newell KA, Deng C, Huang XF (2006) Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172:556–560
Poncelet M, Barnouin M-C, Breliere J-C et al. (1999) Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology 144:144–150
Schneider M (2008) Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13:253–263
Schneider M, Koch M (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28:1760–1769
Schneider M, Koch M (2005) Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 30:944–957
Schneider M, Drews E, Koch M (2005) Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55, 212-2. Behav Pharmacol 16:447–454
Sundram S (2006) Cannabis and neurodevelopment: implications for psychiatric disorders. Hum Psychopharmacol 21:245–254
van Os J, Bak M, Hanssen M et al. (2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156:319–327
Veen ND, Selten JP, van der Tweel I et al. (2004) Cannabis use and age at onset of schizophrenia. Am J Psychiatry 161:501–506
Zammit S, Allebeck P, Andreasson S et al. (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br Med J 325:1199–1203
Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:355–360
Zuardi AW, Rodrigues JA, Cunha JM (1991) Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 104:260–264
Acknowledgements
This research was funded by the Stanley Medical Research Institute (01-315 and 03-NV-003 to FML) and the Koeln Fortune Program (108-2000 to FML). I gratefully acknowledge the contributions of Drs. L. Kranaster, D. Koethe, C.W. Gerth, C. Hoyer, B.M. Nolden, C. Mauss, D. Schreiber, F. Pahlisch, and C. Jöpen to this research.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Leweke, F.M. (2009). Schizophrenia. In: Kendall, D., Alexander, S. (eds) Behavioral Neurobiology of the Endocannabinoid System. Current Topics in Behavioral Neurosciences, vol 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-88955-7_16
Download citation
DOI: https://doi.org/10.1007/978-3-540-88955-7_16
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-88954-0
Online ISBN: 978-3-540-88955-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)